FDA Approves Ciltacabtagene Autoleucel (Carvykti) as Second-Line Multiple Myeloma Treatment: 74% Response Rate
Quick Facts
What Is Ciltacabtagene Autoleucel and How Does CAR-T Therapy Work for Myeloma?
Ciltacabtagene autoleucel (cilta-cel, brand name Carvykti), developed by Legend Biotech and Janssen (Johnson & Johnson), is a chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a protein highly expressed on myeloma cells. The treatment involves collecting a patient's T cells via leukapheresis, genetically engineering them in a specialized manufacturing facility to express two BCMA-binding domains (providing enhanced avidity), expanding the cells, and infusing them back into the patient after lymphodepleting chemotherapy. The engineered T cells then seek out and destroy BCMA-expressing myeloma cells throughout the body.
Originally approved in February 2022 for heavily pretreated myeloma patients who had received four or more prior lines of therapy, Carvykti was subsequently moved to earlier use based on the landmark CARTITUDE-4 trial results. The expanded indication to patients who have received at least one prior line of therapy represents a paradigm shift in myeloma treatment. Previously, CAR-T therapy was reserved as a last resort after multiple relapses; now, patients who relapse after just one prior regimen containing a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody (the current standard triplet frontline therapy) can receive this potentially curative one-time treatment.
What Did the CARTITUDE-4 Trial Results Show?
The CARTITUDE-4 trial, a randomized Phase 3 study published in the New England Journal of Medicine, enrolled 419 patients with lenalidomide-refractory multiple myeloma who had received 1–3 prior lines of therapy across multiple international sites. Patients were randomized 1:1 to cilta-cel (a single infusion after lymphodepletion) or physician's choice of standard regimens (pomalidomide-bortezomib-dexamethasone [PVd] or daratumumab-pomalidomide-dexamethasone [DPd]).
Cilta-cel demonstrated approximately a 76% reduction in the risk of disease progression or death compared to standard therapy (hazard ratio approximately 0.26). Median progression-free survival was not yet reached for the cilta-cel arm at the primary analysis, versus approximately 11.8 months for standard therapy. The overall response rate was 84.6% with cilta-cel, with approximately 73% of patients achieving complete response or better and high rates of minimal residual disease (MRD) negativity. Longer-term follow-up data presented at major hematology conferences have continued to confirm the durability of these responses. The most significant safety concerns included cytokine release syndrome (CRS) in approximately 76% of patients (the vast majority grade 1–2), neurotoxicity including immune effector cell-associated neurotoxicity syndrome (ICANS) in a subset of patients, prolonged cytopenias, and infections requiring monitoring.
What Are the Challenges and Implications for Myeloma Patients?
Despite the compelling clinical data, significant practical barriers remain. CAR-T cell manufacturing requires several weeks from leukapheresis to infusion, during which patients may require bridging therapy to control their disease. Manufacturing slot availability has improved since initial approval but remains constrained, with wait times at major academic centers. Legend Biotech has invested in expanding manufacturing capacity, including facilities in New Jersey and Belgium, aiming to reduce turnaround times.
The wholesale acquisition cost of Carvykti is approximately $465,000 for the one-time treatment, not including hospitalization, monitoring, and supportive care costs that can bring total episode costs substantially higher. However, health economic analyses suggest that cilta-cel may be cost-effective when used in earlier lines of therapy compared to the cumulative costs of multiple subsequent lines of standard treatment. CMS and major commercial payers have established coverage pathways, and outcomes-based contracts have been explored where partial refunds may be provided if patients do not respond. Moving the indication from fourth-line to second-line substantially increases the number of eligible U.S. multiple myeloma patients annually, potentially expanding access to this therapy several-fold compared to the original indication.
Frequently Asked Questions
Adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and whose disease is refractory to lenalidomide. Patients must be fit enough to undergo lymphodepleting chemotherapy and manage potential side effects.
Carvykti is designed as a single, one-time infusion. The engineered CAR-T cells can persist and remain active in the body for months to years. Clinical trial data have shown CAR-T cell persistence in a majority of patients at 12 months. If patients eventually relapse, retreatment with cilta-cel or alternative therapies may be considered.
The most significant risks include cytokine release syndrome (CRS), occurring in approximately 76% of patients (mostly mild), neurotoxicity including movement and cognitive issues (ICANS), prolonged low blood counts (cytopenias), and serious infections. Patients are typically monitored in hospital for 10–14 days post-infusion and must remain near the treatment center for at least 4 weeks.
References
- San-Miguel JF, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Myeloma (CARTITUDE-4). N Engl J Med. 2023;389(4):335-347.
- U.S. Food and Drug Administration. FDA Approves Carvykti for Previously Treated Multiple Myeloma. FDA.gov, April 2024.
- Martin T, et al. Ciltacabtagene Autoleucel, a BCMA-Directed CAR-T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma: Updated Results from CARTITUDE-1. J Clin Oncol. 2023;41(6):1265-1274.
- Berdeja JG, et al. Ciltacabtagene autoleucel, a BCMA-directed CAR-T-cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324.